ApoE facilitates the microglial response to amyloid plaque pathology
Open accessThe DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Abstract
One of the hallmarks of Alzheimer’s disease is the presence of extracellular diffuse and fibrillar plaques predominantly consisting of the amyloid-β (Aβ) peptide. Apolipoprotein E (ApoE) influences the deposition of amyloid pathology through affecting the clearance and aggregation of monomeric Aβ in the brain. In addition to influencing Aβ metabolism, increasing evidence suggests that apoE influences microglial function in neurodegenerative diseases. Here, we characterize the impact that apoE has on amyloid pathology and the innate immune response in APPPS1ΔE9 and APPPS1-21 transgenic mice. We report that Apoe deficiency reduced fibrillar plaque deposition, consistent with previous studies. However, fibrillar plaques in Apoe-deficient mice exhibited a striking reduction in plaque compaction. Hyperspectral fluorescent imaging using luminescent conjugated oligothiophenes identified distinct Aβ morphotypes in Apoe-deficient mice. We also observed a significant reduction in fibrillar plaque–associated microgliosis and activated microglial gene expression in Apoe-deficient mice, along with significant increases in dystrophic neurites around fibrillar plaques. Our results suggest that apoE is critical in stimulating the innate immune response to amyloid pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3. Decreased plaque-associated microgliosis in Apoe-deficient mice. (A) Representative images of APPPS1 and Apoe−/−;APPPS1 mice stained with Iba1 to label microglia and X-34 to label amyloid plaques. (B) Significant reduction in the number of microglia in Apoe−/−;APPPS1 (0.60 ± 0.04, n = 7 mice) mice compared with APPPS1 (1.7 ± 0.12, n = 7) within 15 µm (t[12] = 8.3, P < 0.0001) and 30 µm (2.5 ± 0.18, n = 7 mice versus 4.5 ± 0.28, n = 7 mice); t(12) = 5.9, P < 0.0001, Student’s t test. The number of microglia >30 µm from a plaque in APPPS1 (154.3 ± 7.1, n = 7 mice) compared with Apoe−/−;APPPS1 (150.7 ± 14.9, n = 7 mice) was not significantly different; t(12) = 0.22, P = 0.83, Student’s t test. (C) Representative images of APPPS1ΔE9 and Apoe−/−;APPPS1ΔE9 mice stained with Iba1 and X-34. (D) Significant reduction in the number of microglia within 15 µm of Apoe−/−;APPPS1ΔE9 (1.2 ± 0.17, n = 7 mice), compared with APPPS1ΔE9 (2.2 ± 0.1, n = 11 mice); t(16) =5.6, P < 0.0001, Student’s t test, and within 30 µm (2.8 ± 0.24, n = 7 mice) compared with (4.6 ± 0.16, n = 11 mice); t(16) = 6.5, P < 0.0001, Student’s t test. The number of microglia >30 µm from a plaque in APPPS1ΔE9 (160.3 ± 14.7, n = 11 mice) and Apoe−/−;APPPS1ΔE9 (133.2 ± 8.5, n = 7 mice) were not significantly different; t(16) = 1.4, P = 0.19, Student’s t test. (E) Selected differentially expressed inflammatory gene expression from APPPS1 (n = 6 mice) and Apoe−/−;APPPS1 mice (n = 7 mice). See Table S1 for p-values. (F) Analysis of cytokine levels in the hippocampus of APPPS1 and Apoe−/−;APPPS1 mice. Apoe−/−;APPPS1 mice (n = 13 mice) exhibited a significant reduction in CCL3 compared with APPPS1 mice (n = 11 mice). P < 0.0001, Student’s t test. Bars, 100 µm. ***, P < 0.001.](https://figures.cochat.ai/paper-figures/18ed3f387eff4ebda9af8d5233d33033/apoe-facilitates-the-microglial-response-to-amyloid-plaque-pathology-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies have shown that neurites surrounding amyloid plaques are enriched in the lysosomal marker, lysosome-associated membrane protein 1 (LAMP1) in both human patients with dementia and mouse models of AD29,30.”
From Deletion of SPI1 in microglia exacerbates amyloid pathology by impairing microglial response in Alzheimer’s disease models (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“as TREM2 has been demonstrated to be an ApoE receptor116–119.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglia form a critical interface between APOE genotype and amyloid pathology, mediating A β clearance and restricting local toxicity 25,40 .”
From APOE2 attenuates APOE4-associated amyloid pathology and related toxicity in a mouse model of Alzheimer’s disease (2026) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE also markedly accelerates amyloid deposition (23,24) as well as taumediated neurodegeneration in mouse models (25).”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies showed that apoE is co-deposited in senile plaques and plays a crucial role in fibrillar plaque formation (23, 24).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [24]
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493 · cited 2×
“3 G; Table S1; Keren-Shaul et al., 2017).”
Self-citationTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“Variants in microglial-expressed genes, such as TREM2 and CD33 alter the risk of developing AD, implicating the importance of microglia in the onset and progression of AD (Naj et al., 2011; Griciuc et al., 2013; Guerreiro et al., 2013; Jonsson et al., 2013).”
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · cited 3×
“However, beyond its effect on amyloid, apoE also influences diverse processes in the brain, such as synaptogenesis, phagocytosis, BBB function, and microglial activation (Mauch et al., 2001; Bell et al., 2012; Butovsky et al., 2015; Chung et al., 2016; Krasemann et al., 2017; Shi et al., 2017).”
Self-citationVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“Variants in microglial-expressed genes, such as TREM2 and CD33 alter the risk of developing AD, implicating the importance of microglia in the onset and progression of AD (Naj et al., 2011; Griciuc et al., 2013; Guerreiro et al., 2013; Jonsson et al., 2013).”
Identification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 1×
“ApoE expression is low in microglia in a homeostatic activation state, but is strongly up-regulated by neurodegenerative insults (Butovsky et al., 2014, 2015; Krasemann et al., 2017).”
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · cited 1×
“Variants in microglial-expressed genes, such as TREM2 and CD33 alter the risk of developing AD, implicating the importance of microglia in the onset and progression of AD (Naj et al., 2011; Griciuc et al., 2013; Guerreiro et al., 2013; Jonsson et al., 2013).”
TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736 · cited 1×
“…plaque morphology and increased neuritic dystrophy, suggestive of a role for microglia in shaping the gross structure of plaques and reducing plaque-associated toxicity (Ulrich et al., 2014; Wang et al., 2015, 2016; Yuan et al., 2016; Jay et al., 2017; Song et al., 2017; Ulland et al., 2017).”
Self-citationCNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711 · cited 1×
“However, beyond its effect on amyloid, apoE also influences diverse processes in the brain, such as synaptogenesis, phagocytosis, BBB function, and microglial activation (Mauch et al., 2001; Bell et al., 2012; Butovsky et al., 2015; Chung et al., 2016; Krasemann et al., 2017; Shi et al., 2017).”
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · cited 2×
“Tg2576 mice exhibited a roughly 1:5 ratio of Aβ42/Aβ40 in young animals, compared with an ∼1:1 ratio in APP PS1 and APP PS1ΔE9 mice, which likely results in the accelerated development of Aβ-deposition in APP PS1 and APP PS1ΔE9 mice and the formation of amyloid (Jankowsky et al., 2004; Radde et al., 2006).”
Single App knock-in mouse models of Alzheimer’s disease
Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C. (2014) · Nature Neuroscience · doi:10.1038/nn.3697 · Cited by 1,366 · cited 2×
“20171265 1053 provide additional insight into potential mechanisms underlying our observations (Saito et al., 2014).”
Influential
Cited by
Items 101–200 of 303
Alzheimer’s genes in microglia: a risk worth investigating
Sudwarts, A., & Thinakaran, G. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00679-4 · Cited by 44
“In APP/PS1 mice, the loss of Apoe expression (whole-body knock-out) impaired compaction of amyloid deposits, reduced microglia activation, and increased amyloid deposit-associated neuritic dystrophy [59], producing a similar effect to that of microglial depletion mentioned above [8, 60].”
BackgroundSacher, C., Blume, T., Beyer, L., Peters, F., Eckenweber, F., Sgobio, C., Deussing, M., Albert, N. L., Unterrainer, M., Lindner, S., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.227322 · Cited by 51
“This property needs to be addressed in future studies of Ab-targeting therapies or genetic modifications with differential effects on the expressions of dense and diffuse parts of the plaque (27).”
BackgroundKlingstedt, T., Ghetti, B. F., Holton, J. L., Ling, H., Nilsson, K. P. R., & Goedert, M. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0840-1 · Cited by 52
Self-citationEffect of APOE alleles on the glial transcriptome in normal aging and Alzheimer’s disease
Serrano-Pozo, A., Li, Z., Noori, A., Nguyen, H. N., Mezlini, A., Li, L., Hudry, E., Jackson, R. J., Hyman, B. T., & Das, S. (2021) · Nature Aging · doi:10.1038/s43587-021-00123-6 · Cited by 49
Ethanol exposure alters Alzheimer's-related pathology, behavior, and metabolism in APP/PS1 mice
Day, S. M., Gironda, S. C., Clarke, C. W., Snipes, J. A., Nicol, N. I., Kamran, H., Vaughan, W., Weiner, J. L., & Macauley, S. L. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105967 · Cited by 51
Rao, A. T., Chen, N., Kim, M. J., Blumenfeld, J. R., Yip, O., Liang, Z., Shostak, D. M., Hao, Y., Nelson, M. R., Koutsodendris, N., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.10.005 · Cited by 49
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Da Mesquita, S., & Rua, R. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.03.007 · Cited by 41
Hou, J., Chen, Y., Cai, Z., Heo, G. S., Yuede, C. M., Wang, Z., Lin, K., Saadi, F., Tršan, T., Nguyen, A. T., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj9052 · Cited by 45
“It has been shown that ApoE is the major lipoprotein in the brain ( 4 ) and is present in A β plaques ( 34 ).”
BackgroundSelf-citationThygesen, C., Ilkjær, L., Kempf, S. J., Hemdrup, A. L., von Linstow, C. U., Babcock, A. A., Darvesh, S., Larsen, M. R., & Finsen, B. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00397 · Cited by 44
Prion protein glycans reduce intracerebral fibril formation and spongiosis in prion disease
Sevillano, A. M., Aguilar‐Calvo, P., Kurt, T. D., Lawrence, J. A., Soldau, K., Nam, P., Schumann, T., Pizzo, D. P., Nyström, S., Choudhury, B., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131564 · Cited by 43
“Variations in the decay times have previously been observed for h-FTAA bound to different aggregated morphotypes of amyloid-β (46), as well as prion deposits associated with distinct prion strains (47).”
BackgroundSelf-citationMulti-functional role of apolipoprotein E in neurodegenerative diseases
Islam, S., Noorani, A. A., Sun, Y., Michikawa, M., & Zou, K. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1535280 · Cited by 47
Xiong, M., Wang, C., Gratuze, M., Saadi, F., Bao, X., Bosch, M. E., Lee, C., Jiang, H., Serrano, J. R., Gonzales, E. R., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00610-x · Cited by 40
“5d), similar to what has been observed in amyloid-depositing APOE knockout mice [61].”
BackgroundSelf-citationTajbakhsh, A., Read, M., Barreto, G. E., Ávila-Rodriguez, M., Gheibi-Hayat, S. M., & Sahebkar, A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173873 · Cited by 41
Henningfield, C. M., Arreola, M. A., Soni, N., Spangenberg, E. E., & Green, K. N. (2022) · Glia · doi:10.1002/glia.24105 · Cited by 40
“The increase in plaque size aligns with a previous study utilizing the APP/PS1 mouse model of AD, which found that global ApoE deficiency increased Aβ plaque size, while decreasing amyloid burden (Ulrich et al., 2018).”
BackgroundResultInfluentialHigh-density lipoprotein in Alzheimer's disease: From potential biomarkers to therapeutics
Jin, Y., Chifodya, K., Han, G., Jiang, W., Chen, Y., Shi, Y., Xu, Q., Xi, Y., Wang, J., Zhou, J., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.018 · Cited by 43
Cuperlovic-Culf, M., & Badhwar, A. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1674808 · Cited by 39
“lipoteichoic acids, lipids, phospholipids, high-density lipoproteins (HDL), low-density lipoproteins (LDL), apolipoproteins, clusterin as well as Aβ [24].”
BackgroundFerguson, C. M., Hildebrand, S., Godinho, B. M. D. C., Buchwald, J., Echeverria, D., Coles, A., Grigorenko, A., Vangjeli, L., Sousa, J., McHugh, N., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13703 · Cited by 37
“45,66,86–88 However, unlike many studies, we observed that silencing Apoe promoted the expression of genesinvolvedinimmuneresponsepathways.”
BackgroundSynapses, Microglia, and Lipids in Alzheimer’s Disease
Paasila, P. J., Aramideh, J. A., Sutherland, G. T., & Graeber, M. B. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.778822 · Cited by 46
Zhang, S.-S., Gao, Z., Feng, L., & Li, M. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s483412 · Cited by 40
“34,35 In October 2020, researchers discovered a new gene, FAM171A2, with the ability to control progranulin (PGRN) production in endothelial cells lining blood vessels.”
BackgroundMicroglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development
Biber, K., Bhattacharya, A., Campbell, B. M., Piro, J. R., Rohe, M., Staal, R. G. W., Talanian, R. V., & Möller, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00840 · Cited by 41
Microglial TREM2 at the Intersection of Brain Aging and Alzheimer’s Disease
Qu, W., & Li, L. (2021) · The Neuroscientist · doi:10.1177/10738584211040786 · Cited by 40
Pandey, R. S., Graham, L., Uyar, A., Preuss, C., Howell, G. R., & Carter, G. W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0351-3 · Cited by 37
“in inflammation and microglia related pathways such as osteoclast differentiation, 339 staphylococcus aures infection, phagosome, and endocytosis (Figure 2B), implicating 340 an important role of Apoe in inflammatory and microglia related functions [40-42].”
BackgroundINPP5D modulates TREM2 loss-of-function phenotypes in a β-amyloidosis mouse model
Iguchi, A., Takatori, S., Kimura, S., Muneto, H., Wang, K., Etani, H., Ito, G., Sato, H., Hori, Y., Sasaki, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106375 · Cited by 42
Eskandari‐Sedighi, G., Crichton, M. C., Zia, S., Gomez‐Cardona, E., Cortez, L. M., Patel, Z. H., Takahashi, K., Laurent, C. D. S., Sidhu, G., Sarkar, S., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00734-8 · Cited by 38
“As dense, compact plaques have been shown to have higher levels of associated ApoE [42], we quantified total levels of ApoE in the fractionated brain homogenates and observed significantly higher levels of ApoE in the insoluble fraction of CD33m mice in comparison to the 5XFAD control group (Suppl.”
ResultGabbouj, S., Natunen, T., Koivisto, H., Jokivarsi, K., Takalo, M., Marttinen, M., Wittrahm, R., Kemppainen, S., Naderi, R., Posado-Fernández, A., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.11.008 · Cited by 34
Interactive rather than independent effect of APOE and sex potentiates tau deposition in women
Wang, Y.-T. T., Pascoal, T. A., Therriault, J., Kang, M. S., Benedet, A. L., Savard, M., Tissot, C., Lussier, F. Z., Arias, J. F., Mathotaarachchi, S., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab126 · Cited by 37
Self-citationMa, C., Wu, Y., Song, L., Yin, L., Yin, J.-J., Wang, Q., Yu, J., & Xiao, B. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.355747 · Cited by 39
“However, microglia in pathological states such as AD are activated by a variety of factors and related various receptors on the surface, such as TREM2 and Toll-like receptors (TLRs); these can bind to each other with Aβ and apolipoprotein E (ApoE) and then migrate directionally to the site of injury (Jay et al., 2017;…”
BackgroundKloske, C. M., Dugan, A. J., Weekman, E. M., Winder, Z., Patel, E., Nelson, P. T., Fardo, D. W., & Wilcock, D. M. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlab085 · Cited by 38
Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease
Miziak, B., Błaszczyk, B., & Czuczwar, S. J. (2021) · Pharmaceuticals · doi:10.3390/ph14050458 · Cited by 37
Preman, P., Moechars, D., Fertan, E., Wolfs, L., Serneels, L., Shah, D., Lamote, J., Poovathingal, S., Snellinx, A., Mancuso, R., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00162-7 · Cited by 32
“On the other hand, AD mouse models show limited amyloid plaque pathology in the absence of Apoe (Bales et al, 1999; Holtzman et al, 2000b; Ulrich et al, 2018).”
Yan, H., Wang, W., Cui, T., Shao, Y., Li, M., Fang, L., & Feng, L. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s455881 · Cited by 33
“26,27 In October 2020, a novel gene, FAM171A2, was discovered to regulate the production of progranulin (PGRN), a precursor of vascular endothelial cells.”
BackgroundRusty Microglia: Trainers of Innate Immunity in Alzheimer's Disease
Sfera, A., Gradini, R., Cummings, M., Diaz, E. L., Price, A. I., & Osorio, C. P. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.01062 · Cited by 34
Advances in Modeling Alzheimer's Disease In Vitro
Sharma, N. S., Karan, A., Lee, D.-H., Yan, Z., & Xie, J. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100097 · Cited by 34
Snellman, A., Ekblad, L. L., Tuisku, J., Koivumäki, M., Ashton, N. J., Lantero‐Rodriguez, J., Karikari, T. K., Helin, S., Bucci, M., Löyttyniemi, E., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01209-6 · Cited by 35
The amyloid state of proteins: A boon or bane?
Hassan, M. N., Nabi, F., Khan, A. N., Hussain, M. S., Siddiqui, W. A., Uversky, V. N., & Khan, R. H. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.01.115 · Cited by 30
The Microglial Response to Neurodegenerative Disease
Song, W. M., & Colonna, M. (2018) · Advances in immunology · doi:10.1016/bs.ai.2018.04.002 · Cited by 30
Self-citationGuix, F. X. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24526 · Cited by 31
“ApoE protein would also play a role in the removal of amyloid plaques from the brain by favoring microglial activation and clearance (Ulrich et al., 2018).”
BackgroundKim, B., Dabin, L. C., Tate, M. D., Karahan, H., Sharify, A. D., Acri, D. J., Al-Amin, M. M., Philtjens, S., Smith, D. C., Wijeratne, H. R. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48484-x · Cited by 28
Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer’s disease?
Vecchio, F. L., Bisceglia, P., Imbimbo, B. P., Lozupone, M., Latino, R. R., Resta, E., Leone, M., Solfrizzi, V., Greco, A., Daniele, A., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221081605 · Cited by 28
“Mouse J20 line of hAPPFAD and overexpressing APOE 272-299 ApoE4 (1-271)1 (N-terminal) Decreases Aβ clearance and increases Aβ deposition In vivo/ In vitro Full-length ApoE3 and ApoE4 expressing mice were able to stimulate Aβ clearance Bien-Ly et al.”
BackgroundMicroglial dysfunction in Alzheimer's disease: Mechanisms, emerging therapies, and future directions
Azmal, M., Paul, J. K., Prima, F. S., Haque, A. N. M. S. N. B., Meem, M., & Ghosh, A. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115374 · Cited by 33
Single-synapse analyses of Alzheimer’s disease implicate pathologic tau, DJ1, CD47, and ApoE
Phongpreecha, T., Gajera, C. R., Liu, C. C., Vijayaragavan, K., Chang, A. L., Becker, M., Fallahzadeh, R., Fernandez, R., Postupna, N., Sherfield, E., et al. (2021) · Science Advances · doi:10.1126/sciadv.abk0473 · Cited by 28
Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C., Knight, J. A., Ikezu, T. C., Kurti, A., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00599-3 · Cited by 31
Collagenous Alzheimer amyloid plaque component impacts on the compaction of amyloid-β plaques
Hashimoto, T., Fujii, D., Naka, Y., Kashiwagi‐Hakozaki, M., Matsuo, Y., Matsuura, Y., Wakabayashi, T., & Iwatsubo, T. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01075-5 · Cited by 30
Transcriptional response of murine microglia in Alzheimer’s disease and inflammation
Shippy, D. C., Watters, J. J., & Ulland, T. K. (2022) · BMC Genomics · doi:10.1186/s12864-022-08417-8 · Cited by 27
“Several studies have already highlighted the importance of specific genes involved in microglial metabolism [7] and response to Aβ plaque pathology [8].”
BackgroundSelf-citationGünaydin, C., Sondhi, D., Kaminsky, S. M., Lephart, H. C., Leopold, P. L., Hackett, N. R., Khanna, R., & Crystal, R. G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.003 · Cited by 26
Microglia in Alzheimer’s Disease
Süß, P., & Schlachetzki, J. C. M. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200212155234 · Cited by 27
Björk, L., Klingstedt, T., & Nilsson, K. P. R. (2023) · ChemBioChem · doi:10.1002/cbic.202300044 · Cited by 28
Self-citationThe role of macrophage plasticity in neurodegenerative diseases
Ma, H., Zhu, M., Chen, M., Li, X., & Feng, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00624-7 · Cited by 25
“TREM2 and TLRs can bind to A β and ApoE and then migrate specifically to the site of injury [43, 119, 120].”
BackgroundMaxwell, A. M., Yuan, P., Rivera, B. M., Schaaf, W., Mladinov, M., Prasher, V. P., Robinson, A. C., DeGrado, W. F., & Condello, C. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01298-0 · Cited by 23
“For example, neuroinflammation, in particular plaque-associated microglia activation, is known to affect amyloid conformation [41, 59, 60].”
BackgroundHua, J., Paco, E. G. D., Linck, N., Maurice, T., Desrumaux, C. M., Manoury, B., Rassendren, F., & Ulmann, L. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04784-x · Cited by 23
Microglial Transforming Growth Factor-β Signaling in Alzheimer’s Disease
Vidovic, N., & Spittau, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063090 · Cited by 25
“Interestingly, APOE4 is known to play an essential role in this seeding process [146,155].”
BackgroundJoshi, R., Brezáni, V., Mey, G. M., Guixé‐Muntet, S., Ortega‐Ribera, M., Zhuang, Y., Zivny, A., Werneburg, S., Gracia‐Sancho, J., & Szabó, G. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03203-7 · Cited by 27
The Dual Nature of Microglia in Alzheimer’s Disease: A Microglia-Neuron Crosstalk Perspective
Xie, Z., Meng, J., Wu, Z., Nakanishi, H., Hayashi, Y., Kong, W., Lan, F., Narengaowa, Yang, Q., Qing, H., et al. (2023) · The Neuroscientist · doi:10.1177/10738584211070273 · Cited by 19
The Genetics of Alzheimer’s Disease in the Chinese Population
Gan, C., Zhang, T., & Lee, T. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072381 · Cited by 21
Apolipoprotein E Facilitates Amyloid-β Oligomer-Induced Tau Phosphorylation
Hou, T.-T., Han, Y.-D., Cong, L., Liu, C.-C., Liang, X.-Y., Xue, F.-Z., & Du, Y.-F. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190711 · Cited by 20
Microglial Neuroinflammation in Alzheimer’s Disease: Mechanisms and Therapies
Erdağ, E., & Haskologlu, I. C. (2025) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad2030029 · Cited by 23
“In disease contexts, however, microglial APOE may contribute disproportionately to local immune signaling and lipid dysregulation within plaque-associated regions [33,34].”
Advances in Genetic and Molecular Understanding of Alzheimer’s Disease
Ibáñez, L., Cruchaga, C., & Fernández, M. V. (2021) · Genes · doi:10.3390/genes12081247 · Cited by 22
“(2018) found that Apoe deficient mice presented a significant reduction in fibrillar plaque-associated microgliosis and activated microglial gene expression [8].”
BackgroundXu, Y., Zheng, F., Zhong, Q., & Zhu, Y. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230002 · Cited by 22
“There are many preclinical studies developing APOE -directed therapies in animal models, which will eventually be translated and investigated [70, 71].”
Evidence that Alzheimer’s Disease Is a Disease of Competitive Synaptic Plasticity Gone Awry
Huang, Z. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240042 · Cited by 21
“Most notably, new studies show that a key effect of ApoE removal in vivo may be in the reduction of amyloid plaque compaction, an effect that may be deleterious since it may result in increased amounts of diffuse toxic oligomers [19].”
Biechele, G., Monasor, L. S., Wind-Mark, K., Blume, T., Parhizkar, S., Arzberger, T., Sacher, C., Beyer, L., Eckenweber, F., Gildehaus, F., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.261858 · Cited by 21
“This research gap needs to be closed because the 2 forms have differing neurotoxicity, and there is evidence that alterations in AD-related genes such as TREM2 (triggering receptor expressed on myeloid cells 2) and APOE (apolipoprotein E) alter the net Ab plaque fibrillarity, which would consecutively bias the relatio…”
BackgroundCurrent insights into apolipoprotein E and the immune response in Alzheimer's disease
Lin, P. B., & Holtzman, D. M. (2024) · Immunological Reviews · doi:10.1111/imr.13414 · Cited by 19
“55,56 Treatment of anti-sense oligonucleotide (ASO) targeting APOE from birth can significantly reduce A β plaque accumulation, however, ASO treatment just after A β pathology onset age did not affect plaque load.”
Self-citationMinding the Gap: Exploring Neuroinflammatory and Microglial Sex Differences in Alzheimer’s Disease
Reed-Geaghan, E. G., & Keller-Norrell, P. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417377 · Cited by 19
Amyloid‐β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects
Yu, Y., Yu, S., Battaglia, G., & Tian, X. (2024) · Ibrain · doi:10.1002/ibra.12155 · Cited by 38
“53 On the other hand, the binding of APOE to the competing receptors of A β like lipoprotein ‐ related protein 1 (LRP1) and low ‐ density lipoprotein receptor 1 (LDLR) on astrocytes, microglia, and endothelial cells impaired A β clearance.”
BackgroundWang, P., Chen, Z., & Xing, D. (2020) · Optics Express · doi:10.1364/oe.390874 · Cited by 20
Golden, L. R., Siano, D. S., Stephens, I. O., MacLean, S. M., Saito, K., Nolt, G. L., Funnell, J. L., Pallerla, A. V., Lee, S., Smith, C., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02094-y · Cited by 31
“These results are consistent with studies implicating ApoE in plaque compaction and reflect a similar loss of function as seen in Apoe knockout mice, which also feature reductions in plaque-associated microgliosis 57 .”
Microglial apolipoprotein E particles contribute to neuronal senescence and synaptotoxicity
Wang, N., Cai, L., Pei, X., Lin, Z., Huang, L., Liang, C., Wei, M., Shao, L., Guo, T., Huang, F., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110006 · Cited by 18
“34 Secreted apoE is associated with other proteins and lipids in the form of particles.”
Rahimi, A., Sameei, P., Mousavi, S., Ghaderi, K., Hassani, A., Hassani, S., & Alipour, S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04143-2 · Cited by 18
“The other APOE-targeted strategy is lowering the APOE levels since the genetic deletion of APOE or haploinsufficiency haploinsufficiency lessens the amount of Aβ deposited in the cerebral β-amyloidosis mice models [84, 85].”
Qu, W., Jeong, A., Zhong, R., Thieschafer, J. S., Gram, A., & Li, L. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03082-0 · Cited by 19
“X-34, a Congo red-derived dye, was also used to stain dense core amyloid plaques [24, 25].”
BackgroundLou, T.-W., Tao, B., & Chen, M. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2023.01.032 · Cited by 21
Tate, M., Wijeratne, H. R. S., Kim, B., Philtjens, S., You, Y., Lee, D., Gutierrez, D. A., Sharify, D., Wells, M., Perez‐Cardelo, M., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14243 · Cited by 21
“57,58 ApoE binds A β and is found in abundance within A β plaques.”
Female sex is linked to a stronger association between sTREM2 and CSF p-tau in Alzheimer’s disease
Biel, D., Suárez‐Calvet, M., Dewenter, A., Steward, A., Roemer, S. N., Dehsarvi, A., Zhu, Z., Pescoller, J., Frontzkowski, L. K., Kreuzer, A., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00190-3 · Cited by 16
Braun, D. J., Dimayuga, E. R., Morganti, J. M., & Eldik, L. J. V. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01938-7 · Cited by 18
“Levels of cortical (a) and hippocampal (b) IL-1β, IL-6, TNFα, CXCL1, IL-33, and CCL3 are shown in response to diet and genotype.”
ResultInfluentialTakalo, M., Jeskanen, H., Rolova, T., Kervinen, I., Hellén, M., Heikkinen, S., Koivisto, H., Jokivarsi, K., Müller, S. A., Koivumäki, E.-M., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03387-6 · Cited by 16
“β-Amyloid plaque-associated APOE has been suggested to increase plaque compaction and support microglial responses toward β-amyloid deposition [48, 49].”
Pankiewicz, J. E., Lizińczyk, A. M., Franco, L. A., Diaz, J. R., Martá-Ariza, M., & Sadowski, M. J. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01261-z · Cited by 15
“It also remains unexplored whether apoE is directly involved in the clearance of PrPSc by forming apoE/PrPSc complexes and facilitating their uptake by microglia as it is involved in AD pathogenesis by forming complexes with Aβ within the parenchymal plaques [77].”
BackgroundAssociation between hippocampal microglia, AD and LATE‐NC, and cognitive decline in older adults
Kapasi, A., Yu, L., Leurgans, S. E., Agrawal, S., Boyle, P. A., Bennett, D. A., & Schneider, J. A. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13780 · Cited by 15
“38,39 In the current study, we did not find an association between microglia burden and global A β pathology burden.”
BackgroundCell-specific copper dyshomeostasis mechanism in Alzheimer’s disease
Okafor, M., Faller, P., & Vitale, N. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00504-6 · Cited by 18
“Interestingly Trem2 -defi- cient mice display similar phenotypes compared to Apoe - deficient mice, bringing to light the APOE-TREM2 axis [57].”
Yassaghi, Y., Nazerian, Y., Ghasemi, M., Nazerian, A., Sayehmiri, F., Perry, G. L., & Pourbadie, H. G. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18554 · Cited by 15
“116 Moreover, APOE has a different response according to its isoforms.”
BackgroundShi, M., Chu, F., Tian, X., Aerqin, Q., Zhu, F., & Zhu, J. (2021) · The Neuroscientist · doi:10.1177/1073858420987224 · Cited by 17
Zaletel, I. V., Milutinović, K., Bajčetić, M., & Nowakowski, R. S. (2021) · Microscopy and Microanalysis · doi:10.1017/s1431927621012095 · Cited by 18
“ApoE-deficient mice show reduced fibrillar plaque deposition and less shape compaction (Ulrich et al., 2018), which confirms the influence of ApoE-ϵ 4 on plaque formation through possible glial-mediated inflammatory response (Rodriguez et al., 2014; Ulrich et al., 2018).”
BackgroundMicroglial CD2AP deficiency exerts protection in an Alzheimer’s disease model of amyloidosis
Zhang, L., Huang, L., Zhou, Y., Meng, J., Zhang, L., Zhou, Y., Zheng, N., Guo, T., Zhao, S., Wang, Z., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00789-7 · Cited by 13
Self-citationGenetics and Neuropathology of Neurodegenerative Dementias
Scholz, S. W., & Cobos, I. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001505 · Cited by 13
Casali, B. T., Lin, L. W., Benedict, O., Zuppe, H. T., Marsico, E., & Reed-Geaghan, E. G. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03404-8 · Cited by 15
“Aside from ApoE’s effects on clearance of soluble amyloid [25], microglia also seed ApoE into plaques to facilitate amyloid-plaque compaction [36, 39].”
Lantz, L., Shirani, H., Ghetti, B. F., Vidal, R., Klingstedt, T., & Nilsson, K. P. R. (2023) · Chemistry - A European Journal · doi:10.1002/chem.202203568 · Cited by 14
Self-citationA combinatorial approach for achieving CNS-selective RNAi
Ferguson, C. M., Godinho, B. M. D. C., Echeverria, D., Hassler, M. R., Vangjeli, L., Sousa, J., McHugh, N., Alterman, J. F., Hariharan, V. N., Krishnamurthy, P. M., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae100 · Cited by 12
“Genetic removal of APOE (mouse and human) in AD models reduces A β plaques and improves cognitive outcomes ( 14–18 ).”
BackgroundNetwork dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tau
Butt, O. H., Meeker, K. L., Wisch, J. K., Schindler, S. E., Fagan, A. M., Benzinger, T. L. S., Cruchaga, C., Holtzman, D. M., Morris, J. C., & Ances, B. M. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12375 · Cited by 12
Self-citationHypercholesterolemia drives microglial dysfunction and weakens response to amyloid plaques
Kaye, S. D., Gold, A., Lin, D., Chen, M., Zhu, J., & Gao, J. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115272 · Cited by 11
“DAMs actively modulate Aβ plaque dynamics by compacting fibrils into plaques or clearing them through phagocytosis 21–24 . l Additionally, LDLR has been reported to facilitate Aβ clearance by binding Aβ-ApoE complexes and directing them to lysosomes for degradation, linking LDLR deficiency to both…”
Jiao, H., Ge, Y., Huang, L.-Y., Liu, Y., Wu, B., Lian, P., Hao, Y., Han, S., Li, Y., Wu, K., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00887-0 · Cited by 14
“Interestingly, the disruption of microglia barrier and exacerbated axonal spheroids we observed with Ms4a6d knockout has been a recurring theme related to AD genetic risks, including TREM2 R47H and APOE4 [28, 31, 56].”
Farfara, D., Sooliman, M., Avrahami, L., Royal, T. G., Amram, S., Rozenstein‐Tsalkovich, L., Trudler, D., Blanga‐Kanfi, S., Eldar-Finkelman, H., Pahnke, J., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02823-9 · Cited by 11
Ma, X., Prokopenko, D., Wang, N., Aikawa, T., Choi, Y., Zhang, C. M., Lei, D., Ren, Y., Kawatani, K., Starling, S. C., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106813 · Cited by 10
“Indeed, compromised microglia envelopment around plaques has been shown to disturb amyloid plaque compaction and aggravate axonal dystrophy (Ulrich et al., 2018; Yuan et al., 2016).”
Shoubridge, A. P., Carpenter, L., Flynn, E. F., Papanicolas, L. E., Collins, J., Gordon, D., Lynn, D. J., Whitehead, C., Leong, L. E. X., Cations, M., et al. (2025) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaf053 · Cited by 10
Recent advances in Alzheimer’s disease: From molecular mechanisms to therapeutic strategies
Rudman, M. D., Ulrich, J. D., & Holtzman, D. M. (2026) · Cell · doi:10.1016/j.cell.2026.06.006 · Cited by 18
Self-citationIhsan, N. S. M. N., Sani, S. F. A., Looi, L., Cheah, P., Chiew, S.-F., Pathmanathan, D., & Bradley, D. A. (2023) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2023.06.002 · Cited by 10
Huang, Y., Shan, Y., Qin, W., & Zhao, G. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1158579 · Cited by 11
“Animal experiments also proved that APOE deficiency mice models present decreased amyloid burden in the hippocampus (Ulrich et al., 2018).”
BackgroundThree‐dimensional view of microglia—amyloid plaque interactions
Gotkiewicz, M., Capra, J., Miettinen, P. O., Natunen, T., & Tanila, H. (2024) · Glia · doi:10.1002/glia.24628 · Cited by 13
Strickland, M. R., Wang, Z., Golden, L. R., Wang, H., Lu, P., Ren, Y., Tabor, G. T., Zhao, N., Ulrich, J. D., Han, X., et al. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101000 · Cited by 8
Self-citationBjörk, L., Bäck, M., Lantz, L., Ghetti, B. F., Vidal, R., Klingstedt, T., & Nilsson, K. P. R. (2022) · Chemistry - A European Journal · doi:10.1002/chem.202201557 · Cited by 8
Self-citationMarino, K. M., Squirrell, J. M., Chacko, J. V., Watters, J. J., Eliceiri, K. W., & Ulland, T. K. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.12.540407 · Cited by 8
“However, the number of microglia greater than 30 µm of a plaque surface, a radius that has been shown to contain microglia unaffected by plaque pathology 48 , remained unchanged between 4 and 8 months (Figure S2).”
Self-citationEvolving insights into the identity and function of dark microglia
Flury, A., St-Pierre, M.-K., Ayata, P., & Tremblay, M.-È. (2026) · Trends in Neurosciences · doi:10.1016/j.tins.2025.11.002 · Cited by 8
Ho, G. J., Lam, L. Q., Tran, T. T., Wei, J., & Hashimoto, M. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1430593 · Cited by 8
“…Holtzman, 2022), Ulrich and colleagues found that in APPPS1 Δ E9 and APPPS1-21 transgenic mice, fi brillar A β deposition and also in fl ammatory microgliosis was dramatically reduced in the absence of ApoE, indicating that this may be an important in fl ammatory mediator of A β (Ulrich et al., 2018).”
Background
Metadata
- Authors
- Ulrich, J. D., Ulland, T. K., Mahan, T. E., Nyström, S., Nilsson, K. P., Song, W. M., Zhou, Y., Reinartz, M., Choi, S., Jiang, H., Stewart, F. R., Anderson, E., Wang, Y., Colonna, M., & Holtzman, D. M.
- Affiliations
- Washington University in St. Louis (US)
- Linköping University (SE)
- Radboud University Nijmegen (NL)
- Eli Lilly (United States) (US)
- Corresponding author
- Colonna, Marco
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2018-02-26
- Volume
- 215
- Issue
- 4
- Pages
- 1047-1058
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC5881464
- OpenAlex
- W2790949074
- Cited by
- 297
- References
- 58
- Citations by year
- 2026: 26 · 2025: 29 · 2024: 41 · 2023: 46 · 2022: 44 · 2021: 33 · 2020: 31 · 2019: 32 · 2018: 15
- FWCI
- 19.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- National Institutes of Health (AG047644)
- JPB Foundation
- Cure Alzheimer’s Fund
- NIH (RF1AG05148501, 5-T32CA009547-30)
- Donors Cure Foundation (CCAD201703)
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Keywords
- apolipoprotein E, amyloid-beta, amyloid plaques, microglia, Alzheimer's disease, innate immune response, microglial activation, ApoE-deficient mice, dystrophic neurites
- MeSH terms
- Alzheimer Disease, Amyloid, Animals, Apolipoproteins E, Brain, Disease Models, Animal, Humans, Immunity, Innate, Mice, Transgenic, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Microglia, Mice, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.